BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
Go back to BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 55.95 -0.68 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.63 | 52 Week High | $108.96 | |||
| Open | $56.68 | 52 Week Low | $62.12 | |||
| Day High | $56.81 | P/E | N/A | |||
| Day Low | $55.24 | EPS | $-1.27 | |||
| Volume | 1,682,821 | |||||



